This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
2023 brought us has dogma shredding data on hyponatremia and the importance of different diuretics. It has new therapies for old diseases like IgA and hypertension. New drugs for new diseases like inaxaplin for AMKD. And it has new data on old debates like what IVF is best and do thiazides really prevent kidney stones. It is a great list. Dig in!
TenTweetNephJC on AIN = TenXNephJC on AIN = XXNephJC on AIN…? Twitter not being called twitter is confusing.
Welcome👋to #TenTweetNephJC!
— Nephrology Journal Club (@NephJC) September 28, 2023
"We seek it here,we seek it there.."
Aye,we nephrologists seek it everywhere.
Couple of weeks ago, NephJC discussed the intriguing urinary biomarker study for diagnosis of AIN by @dmoledina et al.
✳️#NephJC catch-up✳️of the damned, elusive chase!👇 pic.twitter.com/OsiMjOaKEA
Basic science week - catch up in only Ten Tweets here.
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) October 26, 2022
✳️10 tweets #NephJC catch-up ✳️
Perplexed by how gene dosage plays a role in ADPKD? Fascinated by futuristic stories of miRNA,CRISPR & want to see an application closer to daily life?
Read on!Here’s some good news for the ADPKD patient in your clinic. pic.twitter.com/44iFttuRJK
